ARQT News and Press, Arcutis Biotherapeutics Inc. From 09/02/22

WESTLAKE VILLAGE, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that Neha Krishnamohan has been appointed to the Arcutis B...

NEW CAMPAIGN FROM ARCUTIS AIMS TO EXPOSE THE IMPACT OF PSORIASIS ON PHYSICAL, MENTAL, AND EMOTIONAL WELLBEING PR Newswire Launched during Psoriasis Action Month, campaign provides tips and tools for speaking about psoriasis with healthcare providers, family, and friend...

A total of 683 adults and children, age 6 years and older, have been enrolled in the INTEGUMENT-2 trial Topline data from both INTEGUMENT-1 and -2 trials expected by end of 2022 Atopic dermatitis affects approximately 26 million adults and children in the United States ...

Arcutis Cares provides ZORYVE™ (roflumilast) cream 0.3% at no cost for financially eligible individuals who are uninsured or have Medicaid or Medicare Part D prescription coverage and cannot afford their medication First ever PAP for a topical psoriasis product WESTLAKE...

Arcutis Biotherapeutics ( NASDAQ: ARQT ) said it launched its plaque psoriasis cream Zoryve in the U.S. In July, the U.S. FDA approved Zoryve (roflumilast) cream 0.3% for topical use to treat plaque psoriasis in people aged 12 years and older. ...

Next-generation topical PDE4 inhibitor for adults and adolescents with plaque psoriasis now available in pharmacies nationwide Effective, safe, and very well-tolerated steroid-free cream that rapidly clear plaques and reduces itch Arcutis committed to ensuring affordable...

Arcutis Biotherapeutics press release ( NASDAQ: ARQT ): Q2 GAAP EPS of -$1.31 beats by $0.12 . Cash, cash equivalents, restricted cash, and marketable securities were $283.4 million as of June 30, 2022, compared to $388.6 million as of December 31, 2021....

Received U.S. Food and Drug Administration (FDA) approval for ZORYVE™ (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis, in individuals 12 years of age and older Announced positive topline results from pivotal Phase 3 tria...

A total of 654 adults and children, age six and older, have been enrolled in the INTEGUMENT-1 trial Enrollment continues in INTEGUMENT-2 with topline data from both trials expected by end of 2022 Atopic dermatitis affects approximately 26 million adults and children in the U.S. ...

Arcutis Biotherapeutics ( NASDAQ: ARQT ) jumps 6.5% after-hours Tuesday on pricing its underwritten public offering of 7.5M shares of its common stock at a public offering price of $20.00/share, representing a premium to the closing price of $19.50/share on August 2, 2022. ...